期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 35, 期 -, 页码 15-25出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2017.04.001
关键词
Treg; Metabolism; Tumor; Concomitant immunity; Glycolysis
资金
- European Union European Research Council Starting Grant (ERC-StG) menTORingTregs [310496]
- Fondazione Italiana Sclerosi Multipla (FISM) [2016/R/18]
- Associazione Italiana per la Ricerca sul Cancro-Cariplo TRansforming IDEas in Ontological Research (TRIDEO) [17447]
- FISM [2014/R/21]
Novel concepts in immunometabolism support the hypothesis that glucose consumption is also used to modulate anti-tumor immune responses, favoring growth and expansion of specific cellular subsets defined in the past as suppressor T cells and currently reborn as regulatory T (Treg) cells. During the 1920s, Otto Warburg and colleagues observed that tumors consumed high amounts of glucose compared to normal tissues, even in the presence of oxygen and completely functioning mitochondria. However, the role of the Warburg Effect is still not completely understood, particularly in the context of an ongoing anti-tumor immune response. Current experimental evidence suggests that tumor-derived metabolic restrictions can drive T cell hyporesponsiveness and immune tolerance. For example, several glycolytic enzymes, deregulated in cancer, contribute to tumor progression independently from their canonical metabolic activity. Indeed, they can control apoptosis, gene expression and activation of specific intracellular pathways, thus suggesting a direct link between metabolic switches and pro-tumorigenic transcriptional programs. Focus of this review is to define the specific metabolic pathways controlling Treg cell immunobiology in the context of anti-tumor immunity and tumor progression. (c) 2017 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据